Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Charge-transfer chemistry of two corticosteroids used adjunctively to treat COVID-19. Part I: Complexation of hydrocortisone and dexamethasone donors with DDQ acceptor in five organic solvents

Abdel Majid A. Adam, Hosam A. Saad, Moamen S. Refat, Mohamed S. Hegab

Department of Chemistry, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia

Deanship of Supportive Studies (D.S.S.), Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia

A R T I C L E   I N F O

Article history:
Received 22 December 2021
Revised 29 March 2022
Accepted 2 April 2022
Available online 08 April 2022

Keywords:
Charge-transfer
Hydrocortisone
Dexamethasone
DDQ acceptor
Liquid–liquid interaction
Organic solvents

A B S T R A C T

COVID-19 is the disease caused by a novel coronavirus (CoV) named the severe acute respiratory syndrome coronavirus 2 (termed SARS coronavirus 2 or SARS-CoV-2). Since the first case reported in December 2019, infections caused by this novel virus have led to a continuous global pandemic that has placed an unprecedented burden on health, economic, and social systems worldwide. In response, multiple therapeutic options have been developed to stop this pandemic. One of these options is based on traditional corticosteroids, however, chemical modifications to enhance their efficacy remain largely unexplored. Obtaining additional insight into the chemical and physical properties of pharmacologically effective drugs used to combat COVID-19 will help physicians and researchers alike to improve current treatments and vaccines (i.e., Pfizer-BioNTech, AstraZeneca, Moderna, Janssen). Herein, we examined the charge-transfer properties of two corticosteroids used as adjunctive therapies in the treatment of COVID-19, hydrocortisone and dexamethasone, as donors with 2,3-dichloro-5,6-dicyano-p-benzoquinone as an acceptor in various solvents. We found that the examined donors reacted strongly with the acceptor in CH₂Cl₂ and CHCl₃ solvents to create stable compounds with novel clinical potential.

Dexamethasone (Fig. 1b) (9α-fluoro-16α-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione) (abbreviated here as DM) is a synthetic glucocorticosteroid well known for its potent anti-inflammatory effects, which are 16 times more potent than prednisolone and up to 25–50 times more potent than hydrocortisone [17–19].

Reactions that involve the transfer of an electronically charged particle from an electron-rich donor (D) molecule to an electron-deficient acceptor (A) molecule (D → A) are known as charge transfer (CT) complexations or donor–acceptor interactions [20–27]. The unique physical, biological, chemical properties of the products resulting from CT interactions have gained the attention of researchers in both basic (physics, chemistry, biochemistry, biology) and applied (engineering, material science, industry, technology, pharmacology, medicine) sciences [21,28–81].

In the past 10 years, we focused on the investigation of the CT interaction of numerous vital and biological active molecules with different kinds of acceptors [82–110]. Now, we seek to explore the CT complexation of two anti-inflammatory glucocorticosteroid compounds, hydrocortisone (HC) and dexamethasone (DM), currently used as adjunctive therapeutics in the treatment of COVID-19 in a series of related publications. The purpose of this

1. Introduction

Since the influenza outbreak of 1918, the COVID-19 outbreak has become the biggest worldwide public health crisis. As of November 22, 2021, COVID-19 has infected more than 258 million people and caused over 5 million casualties worldwide [1–7]. Corticosteroids are a class of chemicals that includes mineralocorticoids, glucocorticoids, and steroid hormones. They have been used clinically as immunomodulatory and anti-inflammatory drugs for more than 70 years to treat oral infections, acute respiratory distress syndrome, and inflammatory diseases [8–14]. Two of the corticosteroids most widely used worldwide as adjunctive therapies in the treatment of COVID-19 are hydrocortisone and dexamethasone. Hydrocortisone (Fig. 1a) (11β,17α,21-trihydroxy-1,4-pregn-4-ene-3,20-dione) (abbreviated here as HC) is a steroidal anti-inflammatory drug and anti-allergic glucocorticoid commonly used in the treatment of inflammation and severe skin allergies [15,16].

Dexamethasone (Fig. 1b) (9α-fluoro-16α-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione) (abbreviated here as DM) is a synthetic glucocorticosteroid well known for its potent anti-inflammatory effects, which are 16 times more potent than prednisolone and up to 25–50 times more potent than hydrocortisone [17–19].

Reactions that involve the transfer of an electronically charged particle from an electron-rich donor (D) molecule to an electron-deficient acceptor (A) molecule (D → A) are known as charge transfer (CT) complexations or donor–acceptor interactions [20–27]. The unique physical, biological, chemical properties of the products resulting from CT interactions have gained the attention of researchers in both basic (physics, chemistry, biochemistry, biology) and applied (engineering, material science, industry, technology, pharmacology, medicine) sciences [21,28–81].

In the past 10 years, we focused on the investigation of the CT interaction of numerous vital and biological active molecules with different kinds of acceptors [82–110]. Now, we seek to explore the CT complexation of two anti-inflammatory glucocorticosteroid compounds, hydrocortisone (HC) and dexamethasone (DM), currently used as adjunctive therapeutics in the treatment of COVID-19 in a series of related publications. The purpose of this
part of work (Part I) was to determine the CT complexation behavior of the HC and DM molecules when complexed with the 2,3-dichloro-5,6-dicyano-p-benzoquinone (commonly termed as DDQ) acceptor (Fig. 2) in five different organic solvents namely methanol (MeOH; S1), ethanol (EtOH; S2), acetonitrile (MeCN; S3), dichloromethane (CH2Cl2; S4), and trichloromethane (CHCl3; S5).

2. Experimental details

2.1. Chemicals

The investigated corticosteroids, hydrocortisone (HC) (362.46 g mol⁻¹; C21H30O5; purity ≥ 98% HPLC) and dexamethasone (DM) (392.46 g mol⁻¹; C22H29FO5; purity ≥ 99% HPLC), were supplied by the Sigma-Aldrich (USA). The examined acceptor is 2,3-dichloro-5,6-dicyano-p-benzoquinone (commonly termed as DDQ) (C8Cl2N2O2; 227.0 g mol⁻¹; purity 98%) was obtained from Merck KGaA (Germany). The spectroscopic-grade solvents methanol (S1) (MeOH), ethanol (S2) (EtOH), acetonitrile (S3) (MeCN), dichloromethane (S4) (CH2Cl2), and trichloromethane (S5) (CHCl3) were obtained from Fluka (Lausanne, Switzerland).

2.2. Spectrophotometric analysis

2.2.1. UV/Visible spectrophotometry

A Cary 7000 UV–Vis-NIR Spectrophotometer [Agilent Technologies Australia, Mulgrave, VICTORIA, Australia] was utilized to record the UV/Vis absorption spectra of the HC-DDQ and DM-DDQ system in each solvent (S1, S2, S3, S4, and S5). The spectra were scanned in the region of 200–800 nm at room temperature. After preparing standard solutions of HC, DM, and DDQ (5 × 10⁻⁴ M) in a specific solvent (S1, S2, S3, S4, or S5), 1 mL of the HC standard solution was mixed with 1 mL of the DDQ standard solution, then brought to 5 mL with the appropriate solvent to generate the HC–DDQ complex. The DM–DDQ complex was generated by adding 1 mL of the DDQ standard solution to 1 mL of the mixture to 5 mL with the appropriate solvent. The UV/Vis spectra of the two soluble CT complexes (HC–DDQ and DM–DDQ) were scanned along with the corresponding free components. These spectra will help to characterize the CT phenomena and identify the λ_CT corresponding to the characteristic CT band for each complex.
2.2.2. Fourier-Transform Infrared (FT–IR) spectrophotometry
An ALPHA Bruker Fourier-Transform Infared Spectrometer (Bruker Optik GmbH; Ettlingen, Germany) was utilized to obtain the FT-IR absorption spectra of the solid CT complexes in each solvent in the region 4000–400 cm\(^{-1}\) at room temperature. After preparing a concentrated solution of HC, DM, and DDQ (two portions) by dissolving 2 mmol of each component in 20 mL of the appropriate solvent (S1, S2, S3, S4, or S5), these concentrated solutions were well-stirred, then mixed together (HC with DDQ and DM with DDQ; 1:1 M ratio). To harvest the solid CT complexes (HC–DDQ and DM–DDQ in each solvent) by slow evaporation, the mixed solutions were left overnight and the formed colored precipitates were removed from the solution by filtration. The collected HC–DDQ and DM–DDQ solid products were purified by washing three times with a small amount of the appropriate solvent and finally, air-dried. The ten purified, dried products were scanned by the IR instrument and plotted in transmission mode.

2.3. Elemental composition
The elemental compositions of the donors (HC and DM) with the DDQ acceptor were determined by collecting the carbon, nitrogen, and hydrogen contents (%) for each CT complex prepared in each solvent (S1, S2, S3, S4, and S5) using a Perkin-Elmer 2400 Series II CHNS Microanalyzer (PerkinElmer Inc., Waltham, MA, USA).

2.4. Stoichiometry of the HC–DDQ and DM–DDQ interaction
Generally, two methods based on the UV/Vis absorption spectra are applied to obtain the stoichiometric reaction of the CT complexation, the spectrophotometric titration method and Job’s continuous variation method. The HC and DM stoichiometric interactions with the DDQ acceptor were determined in each solvent (S1, S2, S3, S4, or S5) using both methods.

3. Results and discussion
3.1. Ultraviolet–visible (UV/Vis) characteristics
3.1.1. Donors and acceptor
The donors (HC and DM) are soluble in the S1 and S2 solvents; for the other solvents (S3, S4, and S5), slight heat is required to solubilize the corticosteroids used in the present study. All of the resulting solutions were colorless. In contrast, the DDQ acceptor’s solubility and the resultant solutions varied according to the solvent. As with the two donors, the DDQ molecule was easily dissolved in the S1 and S2 solvents and, with gently heating, in the other three solvents. The resultant solutions in all of the solvents were colored as indicated in Fig. 3. Fig. 4 contains the UV/Vis spectra of the DDQ in each solvent (S1, S2, S3, S4, and S5). Its absorption characteristics depend on the solvent type and can be classified into three categories:

(a) DDQ in the S1 and S2 solvents:
DDQ behaved similarly in the S1 and S2 solvents. DDQ solubilized in the S1 and S2 created orange-colored solutions that absorbed in UV/Vis region from 285 to 600 nm. The molecule displayed two characteristic bands in the region, one in the UV region (296 nm), and one in the Vis region (350 nm). The one in the UV region was a very strong, narrow band with \(\lambda_{\text{max}}\) at 296 nm. The band located in the Vis region was a broad, medium-intensity band with a hill-like shape. This broad band had its \(\lambda_{\text{max}}\) at 350 nm with a long tail that ranged from 380 to nearly 600 nm. The intensity of the tail gradually decreased from 380 to 600 nm. In the S1 solvent, this broad band was less intense and had a belly-like or paunch shape; while in the S2 solvent, it was more intense and had a clear hill-like shape. Generally, DDQ absorbed in the same manner in the S1 and S2 solvents but generated a more clearly defined shape in the S2 solvent.

(b) DDQ in the S4 and S5 solvents:
DDQ behaved very similarly in the S4 and S5 solvents. DDQ’s dissolution in these two solvents yielded two deep yellow solutions that absorbed in UV/Vis region from 287 to nearly 480 nm. The very strong and narrow band displayed by DDQ in the S4 and S5 solvents also appeared when DDQ was dissolved in the S3 and S4 solvents, but it became narrower, and its \(\lambda_{\text{max}}\) blue-shifted from 296 nm in S1 and S2 to 293 nm in the S3 and S4 solvents. Also, the broad band displayed by DDQ in the S1 and S2 solvents also appeared when DDQ was solubilized in the S4 and S5 solvents, but its shape changed from a small hill to a large mountain, and its \(\lambda_{\text{max}}\) blue-shifted by \(\sim 10\) nm (from 350 nm in S1 and S2 to 339 nm in S4 and S5). The broad band appeared in the S4 and S5 solvents but without the long tail seen in the S1 and S2 solvents.

(c) DDQ in the S3 solvent:
DDQ in the S3 solvent exhibited absorption characteristics that differed from those of the other four solvents. The DDQ-S3 solution had a distinct brown color. The very strong, narrow band observed when DDQ was dissolved in the other solvents broadened in the S3 solvent with an approximate width of 32 nm (from 288 to 320 nm).
and a $\lambda_{\text{max}}$ at 298 nm. The medium-intensity, broad band at 350 nm when DDQ was dissolved in the S1 and S2 solvents and at 339 nm in the S4 and S5 solvents, became very weak and close to fading when DDQ was dissolved in the S3 solvent. Instead of this band, a new, strong, very broad band appeared at a much longer wavelength. This wide band ranged from 380 to 625 nm and centered at 460 nm. This new broad band, which was not detected when DDQ was dissolved in the S1, S2, S4, or S5 solvents, is the distinguishing band that characterizes the DDQ solution in the S3 solvent. Table 1 summarizes the characteristic absorption bands that appear when the DDQ acceptor was dissolved in the investigated solvents.

### 3.1.2. CT complexes

Fig. 5 presents the UV/Vis spectra of the HC–DDQ CT complexes in the S1, S2, S3, S4, and S5 solvents, along with that of the free components (HC and DDQ), while Fig. 6 contains those corresponding to the DM–DDQ CT complexes. Generally, the HC and DM molecules behaved similarly when CT complexed with DDQ. This behavior was the same in all solvents, due to the similar chemical structures shared by the HC and DM molecules. This also indicates that the C–F bond present only in the DM molecule does not affect the CT properties between the DM donor and the DDQ. Two categories can be applied to confirm the occurrence of a CT complexation reaction using the UV/Vis spectra of the free donor (D), free acceptor (A), and a mixture between the donor and the acceptor. These categories are:

- (a) An increase (with or without broadening) in the intensity of the characteristic absorption band in the UV/Vis spectra of the donor, acceptor, or both.
- (b) The formation of a new band in the UV/Vis spectra of the (D + A) system where no measurable absorption was displayed by the free donor and acceptor.

Figs. 5 and 6 indicate that when the HC and DM molecules complexed with the DDQ acceptor, the intensity of the absorption bands of the DDQ accepter was strongly enhanced (Category a). This was the case for all HC–DDQ and DM–DDQ CT complexes prepared in the different solvents. After complexation, the $\lambda_{\text{max}}$ of the DDQ's absorption bands remained at the same position as in the free DDQ or underwent a very slight shift (2–4 nm).

### 3.2. Bandgap energy

The following equation was used to determine the bandgap energy ($E_g$):

$$\frac{(\alpha \text{hv})^{1/2}}{\text{hv}} = A (\text{hv} - E_g)$$

where $A$ is a proportionality constant, $\nu$ is the light frequency, $h$ is the Planck constant, $\alpha$ is the absorption coefficient, and $E_g$ is the bandgap energy. The exponent ($1/n$) denotes the nature of the electronic transition, whether indirect or direct and whether forbidden or allowed: $n = 3$ (indirect, forbidden transitions), $n = 3/2$ (direct, forbidden transitions), $n = 2$ (indirect, allowed transitions), and $n = 1/2$ (direct, allowed transitions). Plots of $\nu$ (eV) against $(\alpha \text{hv})^{1/2}$ for DDQ solubilized in the investigated solvents (S1, S2, S3, S4, and S5) are given in Fig. 7, while those for the corresponding HC–DDQ and DM–DDQ CT complexes in each solvent are illustrated in Fig. 8. The observed $E_g$ values from these plots are listed in Table 2.

The solution of free DDQ in the S1 solvent had the highest $E_g$ value (3.595 eV) compared with the other solvents, while the DDQ solution in the S3 solvent had the lowest value of $E_g$ (1.625 eV). This outcome indicates that the $E_g$ value of the DDQ acceptor depends strongly on the type of solvent (Fig. 9). The $E_g$ of the DDQ solution in the investigated solvents decreased in the following order: $S_1 > S_2 > S_5 > S_4 > S_3$. After DDQ complexed with HC or DM in the S1 and S2 solvents, the value of $E_g$ decreased greatly, approximately by half. In the S3 solvent, the $E_g$ value also decreased but not by as much as in the S1 and S2 solvents. Interestingly, when DDQ interacted with HC or DM in the S4 and S5 solvents, the value of $E_g$ remained unchanged.

### 3.3. HC–DDQ and DM–DDQ stoichiometry

The solid CTCs of the DDQ acceptor with the HC and DM molecules (HC–DDQ and DM–DDQ) were elementally characterized by Perkin-Elmer CHNS Elemental Analyzer (fully automated), and the obtained results in terms of carbon, hydrogen, and nitrogen content (%) are listed in Table 3. The C%, H%, and N% data measured by the instrument aligned with the content values computed theoretically from the molecular formula of the solid CT complexes. The elemental data presented in Table 3 revealed that the stoichiometry of the CT reaction between DDQ and HC or DM in all solvents proceeded at a 1:1 M ratio.

### 3.4. HC–DDQ and DM–DDQ stoichiometry

Generally, two methods use UV/Vis absorption spectra to obtain the stoichiometry of a CT complexation, the spectrophotometric titration method and Job’s continuous variation method. The HC and DM stoichiometric interactions with the DDQ acceptor were determined in each solvent (S1, S2, S3, S4, or S5) using both methods. Fig. 10 depicts the relative composition of the HC and DM donors with the DDQ acceptor in the five solvents (S1, S2, S3, S4, and S5) determined by the spectrophotometric titration, while the values generated by Job’s continuous variation are given in Fig. 11. Both methods suggest that the interaction between each donor (HC and DM) with the DDQ proceeded at a 1:1 M ratio in all of the investigated solvents, as did the solid-state reactions between the donors and DDQ based on the CHN elemental results.

### 3.5. Determination of formation constant and molar absorptivity

Determining the molar absorptivity (termed as $e_{\text{max}}$) and the formation constant (termed as $K_{\text{CT}}$) for all of the prepared CT complexes were conducted based on the Benesi–Hildebrand equation (1:1) (Eq. (1)) [111]:

$$\frac{C_D}{C_A} = \frac{1}{K_{\text{CT}} e_{\text{max}}} + \frac{C_A + C_D}{e_{\text{max}}}$$

### Table 1

| Compound       | Characteristic absorption bands (nm) of the free DDQ acceptor in the investigated and the corresponding CT complex. |
|----------------|------------------------------------------------------------------------------------------------------------------|
|                | UV | Vis |
|----------------|----|-----|
| DDQ acceptor   | 296| 298 |
| HC–DDQ complex | 292| 295 |
| DM–DDQ complex | 297| 297 |
In this equation, \( A \) is the absorbance of the CT band, and \( C_a \) and \( C_d \) are the initial concentrations of the acceptor and donor molecules, respectively. In a graphical representation of Eq. (1), plotting the values of \( \frac{(C_a - C_d)}{A} \) versus the values of \( \frac{(C_a + C_d)}{e_{\max}} \) generates a straight line for which \( \frac{1}{e_{\max}} \) is the slope and \( \frac{1}{K_{CT} e_{\max}} \) the intercept. Figs. 12 and 13 contain the Benesi–Hildebrand diagram for the HC–DDQ and DM–DDQ interactions in various solvents, respectively. The derived \( K_{CT} \) and \( e_{\max} \) values for all of the prepared CT complexes are listed in Table 4. Data in Table 4 support that the CT complexes of HC and DM with DDQ showed the highest \( K_{CT} \) and \( e_{\max} \) in the S4 and S5 solvents (non-polar solvents).

### 3.6. Determination of transition dipole moment and oscillator strength

The transition dipole moment and the oscillator strength have been investigated for all of the prepared CT complexes in various...

---

![Figure 5](image-url)  
**Fig. 5.** The UV/Vis spectra of the HC–DDQ CT complexes in each solvent (S1, S2, S3, S4, and S5) along with their components (at concentration of \( 5 \times 10^{-4} \text{ M} \)).
solvents to understand the CT characteristics from the donor (HC or DM) to the acceptor (DDQ). The oscillator strength (termed as $f$) is a dimensionless quantity that expresses the transition probability of the band. It states that during the adsorption to emission process in a molecule or atom, the possibility of several electromagnetic radiation transitions from the ground state to the excited state in energy levels exists. The value $f$ can be derived using Eq. (2) [112]:

$$f = 4.32 \times 10^{-8} \ell_{\text{max}} n_{1/2}$$  \hspace{1cm} (2)

In this equation, $\ell_{\text{max}}$ is the full-width at half-maximum (FWHM) in cm$^{-1}$. The transition dipole moment ($\mu_{\text{eq}}$ in Debye), which used to estimate whether a particular transition is allowed regarding the transient dipole moment induced in the molecule during the transition from a bonding $\pi$ orbital to an antibonding $\pi^*$ orbital. $\mu_{\text{eq}}$ assesses the possibility of radiative transition in a molecule.

Fig. 6. The UV/Vis spectra of the DM–DDQ CT complexes in each solvent (S1, S2, S3, S4, and S5) along with their components.
from the initial to final states in various solvents. $\mu_{eg}$ can be calculated by an equation derived by Tsubumora and Lang [113] (Eq. (3)):

$$m_{eg}^2 = \frac{f}{(4.32 \times 10^{-7} n)}$$  \hspace{1cm} (3)

In this equation, $v$ is the wavenumber in cm$^{-1}$. From the data listed in Table 4, the CT complexes of HC and DM with DDQ created high values of $f$ and $\mu_{eg}$ in the S4 and S5 solvent (non-polar solvents). The high values of $f$ and $\mu_{eg}$ suggest a strong interaction between the HC–DDQ and DM–DDQ pairs in the S3 and S4 solvents, respectively, with relatively high probabilities for CT transitions. A very strong linear relationship exists between the $f$ and $\mu$ values ($r = 0.9991$ for HC complexes; $r = 0.9963$ for DM complexes) (Fig. 14). This strong, positive correlation suggests that the $f$ values of the CT complexes in liquid-state increased as their $\mu_{eg}$ values increased.

![Fig. 7. Plotting the $h\nu$ (eV) versus $(ah\nu)^{3/2}$ for the DDQ acceptor in the investigated solvents (S1, S2, S3, S4, and S5).](image-url)
3.7. FT-IR analysis

The FT-IR spectra obtained for the pure HC and DM molecules are presented in Fig. 15a. The characteristic bands of HC were located at 3414 cm$^{-1}$ ν(O–H), 2920 cm$^{-1}$ [ν(CH$_3$), ν(CH$_2$)], 1704 cm$^{-1}$ ν(C=O) for the carboxylic group, 1642 cm$^{-1}$ ν(C=O) for the carbonyl group, 1434 cm$^{-1}$ δ$_{scf}$(CH$_3$), 1372 cm$^{-1}$ δ$_{rock}$(CH$_3$), 1351 cm$^{-1}$ δ$_{scf}$(CH$_2$), 1277 cm$^{-1}$ δ$_{rock}$(CH$_2$), 1234 cm$^{-1}$ τ(–CH–C–),

**Fig. 8.** Plotting the $hν$ (eV) versus ($hν$)$^{1/2}$ for the HC–DDQ and DM–DDQ CT complexes in the investigated solvents.

| Compound                  | $E_g$ (eV) | S1  | S2  | S3  | S4  | S5  |
|---------------------------|------------|-----|-----|-----|-----|-----|
| DDQ acceptor              | 3.595      | 2.818 | 1.625 | 2.264 | 2.361 |
| HC–DDQ complex            | 1.508      | 1.436 | 1.219 | 2.276 | 2.201 |
| DM–DDQ complex            | 1.376      | 1.365 | 1.304 | 2.230 | 2.376 |

3.7. FT-IR analysis

The FT-IR spectra obtained for the pure HC and DM molecules are presented in Fig. 15a. The characteristic bands of HC were located at 3414 cm$^{-1}$ ν(O–H), 2920 cm$^{-1}$ [ν(CH$_3$), ν(CH$_2$)], 1704 cm$^{-1}$ ν(C=O) for the carboxylic group, 1642 cm$^{-1}$ ν(C=O) for the carbonyl group, 1434 cm$^{-1}$ δ$_{scf}$(CH$_3$), 1372 cm$^{-1}$ δ$_{rock}$(CH$_3$), 1351 cm$^{-1}$ δ$_{scf}$(CH$_2$), 1277 cm$^{-1}$ δ$_{rock}$(CH$_2$), 1234 cm$^{-1}$ τ(–CH–C–),
 responding wavenumbers for the DM molecule were 3393, 984, and 685 cm\(^{-1}\). The absorption spectrum of the DM molecule indicated that the intense characteristic bands of DM appeared at 3393 cm\(^{-1}\) \((\nu(C\equiv O))\), 2946 cm\(^{-1}\) \([\nu(CH_2)]\), and 1713 cm\(^{-1}\) \((\nu(C\equiv O))\) of the carboxylic group, 1660 and 1618 cm\(^{-1}\) \(\nu(C\equiv O)\) of the carboxylic group, 1543 cm\(^{-1}\) \(\delta_{\text{cyclic(CH$_2$)}}\), 1403 cm\(^{-1}\) \(\delta_{\text{cyclic(CH$_3$)}}\), 1280 cm\(^{-1}\) \(\nu(C\equiv F)\), 1239 cm\(^{-1}\) \(\delta_{\text{cyclic(CH$_3$)}}\), 1207 cm\(^{-1}\) \((\nu(CH\equiv C))\), 1127 cm\(^{-1}\) \(\nu(C\equiv C)\), 1054 cm\(^{-1}\) \((\nu(C\equiv O))\), 984 cm\(^{-1}\) \(\nu(C\equiv O)\) in-plane bending), 897 cm\(^{-1}\) \(\delta_{\text{cyclic(CH$_2$)}}\), \(\delta_{\text{cyclic(CH$_3$)}}\) deformation), 855 cm\(^{-1}\) \(\nu(C\equiv H)\) out-of-plane bending), 612 cm\(^{-1}\) \(\delta_{\text{cyclic(CH$_2$)}}\), 536 cm\(^{-1}\) \(\delta_{\text{cyclic(CH$_3$)}}\), and 482 cm\(^{-1}\) \(\nu(C\equiv C)\) in-plane bending). The characteristic vibrations for the HC and DM molecules were:

(i) \(O\equiv H\) vibrations

Both the HC and DM molecules contain three \(O\equiv H\) bonds. The three characteristic vibrations of the \(O\equiv H\) bond (in-plane and out-of-plane bending, stretching vibrations) resonated at 3414, 936, and 685 cm\(^{-1}\), respectively, in the HC molecule, while the corresponding wavenumbers for the DM molecule were 3393, 984, and 690 cm\(^{-1}\), respectively. The \(\nu(O\equiv H)\) vibrations appeared in both molecules as a broad, medium to high-intensity band.

(ii) \(C\equiv F\) vibrations

Just the DM molecule contained one \(C\equiv F\) bond. This bond is the main difference between the structure of DM and HC. In the IR spectrum of the DM molecule, the \(\nu(C\equiv F)\) vibrations were observed at 1280 cm\(^{-1}\) in accordance with a previous report [114].

(iii) \(C\equiv O\) vibrations

Both the HC and DM molecules contain two \(C\equiv O\) bonds. One belongs to the carboxylic group and the other to the carbonyl group. The strong band appearing at 1704 cm\(^{-1}\) in HC and at 1713 cm\(^{-1}\) could be assigned to the \(\nu(C\equiv O)\) of the carboxylic group. The very strong bands at 1642 cm\(^{-1}\) (HC) and 1660 cm\(^{-1}\) (DM) conjugated to the \(\equiv C\equiv O\) bond of the carbonyl group.

(iv) Methyl and methylene group vibrations

The HC molecule contains eight methylene (CH\(_2\)) and two methyl (CH\(_3\)) groups. The DM molecule has five methylene (CH\(_2\)) and three methyl (CH\(_3\)) groups. Both molecules displayed a broad absorption band with a medium-intensity center at 2920 cm\(^{-1}\) for HC and at 2946 cm\(^{-1}\) for DM. The asymmetric and symmetric stretching modes of the CH\(_3\) and CH\(_2\) groups absorb around this area and, because HC and DM have multiple CH\(_3\) and CH\(_2\) groups, this band was broad in the spectra of both molecules. The CH\(_3\) groups gave rise to four bending vibrational modes: \(\delta_{\text{cyclic(CH$_2$)}}\), \(\delta_{\text{cyclic(CH$_3$)}}\), \(\delta_{\text{wag(CH$_2$)}}\), and \(\delta_{\text{wag(CH$_3$)}}\). These appeared at 1343, 1372, 890, and 636 cm\(^{-1}\), respectively, for the HC molecule and at 1448, 1403, 897, and 612 cm\(^{-1}\), respectively, for the DM molecule. The CH\(_2\) groups in the HC absorbed at 1351, 1277, 779, and 566 cm\(^{-1}\) due to the bending vibrations of \(\nu(CH\equiv CH, \nu(CH\equiv CH, \nu(CH\equiv CH, \nu(CH\equiv CH. The corresponding wavenumbers for the DM molecule were 1358, 1239, 761, and 536 cm\(^{-1}\), respectively [115,116].

(v) \(C\equiv O\) vibrations

The stretching vibration of the \(C\equiv O\) bond was identified as a very strong band at 1041 cm\(^{-1}\) (HC) and 1054 cm\(^{-1}\) (DM).

From the FT-IR spectrum of free DDQ [Fig. 15b], the detected bands were 2238, 1675, 1557, 1171, and (893, 798, 720) cm\(^{-1}\), which corresponds to the \(\nu(C\equiv N)\), \(\nu(C\equiv O)\), \(\nu(C\equiv C)\), \(\delta(C\equiv C)\), and \(\nu(C\equiv C)\) vibrations, respectively. The DDQ molecule has three different types of electron-withdrawing groups: two cyan groups, two carbonyl groups, and two chloro groups. All of these withdrawing groups take electrons from the aromatic ring of the DDQ molecule, thereby decreasing the electron density of the aromatic ring and increasing the aromatic ring's need for electrons. This situation makes the DDQ molecule a strong electron-deficient unit. When the DDQ acceptor interacted with the HC or DM molecules, it accepted an electronic charge from the donating sites of the HC or DM molecules [117–121]. This charge transfer from the donors (HC and DM) to the acceptor (DDQ), (HC → DDQ; DM → DDQ) affects all of the characteristic IR absorption bands of the free donors as well as that of the free acceptor, as seen in the FT-IR spectra of the HC–DDQ and DM–DDQ CT complexes prepared in

### Table 3

CHN elemental results of the HC–DDQ and DM–DDQ CT complexes prepared in the S1, S2, S3, S4, and S5 solvents.

| Solvent | HC–DDQ complex | DM–DDQ complex |
|---------|----------------|----------------|
|         | C% Calc. Obtained | C% Calc. Obtained | C% Calc. Obtained | C% Calc. Obtained |
|         | H% Calc. Obtained | H% Calc. Obtained | H% Calc. Obtained | H% Calc. Obtained |
|         | N% Calc. Obtained | N% Calc. Obtained | N% Calc. Obtained | N% Calc. Obtained |
| S1      | 59.04 59.15 5.09 5.31 | 4.75 4.64 | 58.12 57.95 4.68 4.84 | 4.52 4.75 |
| S2      | 59.04 58.93 5.09 5.30 | 4.75 4.85 | 58.12 57.91 4.68 4.55 | 4.52 4.70 |
| S3      | 59.04 58.91 5.09 4.95 | 4.75 4.66 | 58.12 58.03 4.68 4.79 | 4.52 4.72 |
| S4      | 59.04 59.16 5.09 5.28 | 4.75 4.70 | 58.12 58.35 4.68 4.57 | 4.52 4.34 |
| S5      | 59.04 59.10 5.09 4.97 | 4.75 4.88 | 58.12 58.26 4.68 4.53 | 4.52 4.38 |
various solvents (S1, S2, S3, S4, and S5) presented in Figs. 16a and 16b. The band resulting from the C≡N stretching vibrations of the DDQ acceptor shifted from 2238 cm⁻¹ to a lower frequency around 2225 cm⁻¹ in the CT complexes with HC and to ~2232 cm⁻¹ in the CT complexes with DM. The bands belonging to the ν(C=O) in the free HC molecule were affected in their position and intensity after complexation with DDQ. They shifted from 1704 and 1642 cm⁻¹ in the free HC molecule to around ~1717 and ~1615 cm⁻¹ in the HC–DDQ complexes. The same was observed for the DM–DDQ complexes, the bands were shifted from 1713 and 1660 cm⁻¹ in the free DM sample to around ~1698 and ~1675 cm⁻¹ in the DM–DDQ complexes.
4. Conclusions

COVID-19 is an ongoing and relapsing epidemiologic phenomenon. This work represents our contribution to the global efforts to stop the spread of the COVID-19 pandemic and the associated economic, medical, and psychological costs by obtaining a vaccine or cure for this disease. Providing new insight into the CT properties of pharmacologically effective drugs used to combat the COVID-19 pandemic could help researchers alike to develop the treatments and vaccines. Several drugs have been tested, and one class of drugs has received considerable attention, corticosteroids. Two drugs of this class are widely used as adjunctive therapies in the treatment of COVID-19, hydrocortisone (HC) and dexamethasone (DM). Herrin, we prepared 10 CT complexes of HC and DM molecules with the DDQ acceptor. The CT complexes were prepared in five different solvents (S1, S2, S3, S4, and S5).

![Graphs showing absorbance vs. mole fraction of DDQ for different solvents (S1-S5)](Fig. 11. The composition of donors (HC or DM) and DDQ in different solvents (S1, S2, S3, S4, and S5) established by the Job’s continuous variation method.)
Fig. 12. The Benesi-Hildebrand diagram for the HC donor and DDQ interaction in various solvents.

Fig. 13. The Benesi-Hildebrand diagram for the DM donor and DDQ interaction in various solvents.

Fig. 14. Linear correlation between transition dipole moment ($\mu_{eq}$) and oscillator strength ($f$).

Fig. 15a. IR spectra of free the donors (HC and DM).

**Table 4**

| Solvent | HC–DDQ CT complexes | DM–DDQ CT complexes |
|---------|---------------------|---------------------|
|         | $\lambda_{max}$ (nm) | $K_{CT}$ (L mol$^{-1}$) | $\varepsilon_{max}$ (L mol$^{-1}$ cm$^{-1}$) | $f$ | $\mu$ (Debye) | $\lambda_{max}$ (nm) | $K_{CT}$ (L mol$^{-1}$) | $\varepsilon_{max}$ (L mol$^{-1}$ cm$^{-1}$) | $f$ | $\mu$ (Debye) |
|---------|---------------------|---------------------|---------------------|----|---------------------|---------------------|---------------------|---------------------|----|---------------------|
| S1      | 350                 | $25.1 \times 10^5$ | $18.26 \times 10^4$ | 1.972 | 12.11 | 350                 | $25.2 \times 10^5$ | $20.16 \times 10^4$ | 2.177 | 12.72 |
| S2      | 350                 | $28.3 \times 10^5$ | $29.90 \times 10^4$ | 2.583 | 13.86 | 350                 | $18.6 \times 10^5$ | $29.32 \times 10^4$ | 2.532 | 13.72 |
| S3      | 460                 | $33.6 \times 10^5$ | $30.77 \times 10^4$ | 2.659 | 13.85 | 460                 | $21.8 \times 10^5$ | $14.35 \times 10^4$ | 0.629 | 7.84 |
| S4      | 340                 | $41.5 \times 10^5$ | $35.16 \times 10^4$ | 3.037 | 14.81 | 340                 | $32.5 \times 10^5$ | $35.08 \times 10^4$ | 3.031 | 14.80 |
| S5      | 340                 | $41.5 \times 10^5$ | $35.16 \times 10^4$ | 3.037 | 14.81 | 340                 | $49.2 \times 10^5$ | $40.50 \times 10^4$ | 3.499 | 15.9  |
Both molecules behaved similarly when complexed with DDQ in each solvent. We found that both HC and DM strongly complexed with DDQ in the S4 and S5 solvents.

**CRediT authorship contribution statement**

**Abdel Majid A. Adam:** Data curation, Funding acquisition, Project administration, Writing – original draft, Writing – review & editing.  
**Hosam A. Saad:** Supervision, Conceptualization, Software, Validation, Visualization.  
**Moamen S. Refat:** Supervision, Conceptualization, Software, Validation, Visualization.  
**Mohamed S. Hegab:** Investigation, Formal analysis, Methodology, Resources.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Acknowledgements**

This work was supported by the Taif University Researchers Supporting Project Number (TURSP-2020/02), Taif University, Taif, Saudi Arabia. The authors are very grateful to Dr. Leah Boyer for editing and reviewing the manuscript.

**References**

[1] J. Andreani, M. Le Bideau, I. Duflot, P. Jardot, C. Rolland, M. Boxberger, N. Wurtz, J. Rolain, P. Colin, J. La Scola, D. Raoult, In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb. Pathog. 145 (2020) 104228.

[2] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, D.F. Gao, D. Phil, W. Tan. A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med. 382 (2020) 727–733.

[3] Organization WH, WHO director-General’s opening remarks at the media briefing on COVID-19, 11 March 2020, Geneva, Switzerland, 2020.

[4] L. Pasin, P. Navalesi, A. Zangrillo, A. Kuzovlev, V. Likhvantsev, L.A. Hajjar, S. Fresilli, M.V.G. Lacerda, G. Landoni, Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized clinical trials. J. Cardiothorac. Vasc. Anesth. 35 (2) (2021) 578–584.

[5] Johns Hopkins Coronavirus Resource Center, COVID-19 Data in Motion, Accessed August 30, 2021. <https://coronavirus.jhu.edu>.

[6] M. Alkotaji, Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2, Int. J. Antimicrob. Agents 56 (6) (2020) 106192.

[7] Y. Zheng, J. Shang, Y. Yang, C. Liu, Y. Wan, Q. Geng, M. Wang, R. Baric, F. Li. Lysosomal proteases are a determinant of coronavirus tropism, J. Virol 92 (2018) e01504–e1518.

[8] D. Annane, Corticosteroids for COVID-19, J. Intens. Med. 1 (2021) 14–25.

[9] M.A. Gonzalez-Moles, P. Morales, A. Rodriguez-Archilla, I.R. Isabel, S. Gonzalez-Moles, Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution, Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 93 (3) (2002) 264–270.

[10] M. Kosaka, Y. Yamazaki, T. Marumo, K. Sakaguchi, S. Sawaki, Corticosteroids as adjunctive therapy in the treatment of coronavirus disease, A report of two cases and literature review, J. Infect. Chemother. 27 (2021) (2019) 94–98.

[11] A.K. Singh, S. Majumdar, R. Singh, A. Misra, D. Metab, Syndr.: Clin. Res. Rev. 14 (2020) 971–978.

[12] S.C. Sweetman (Ed.), Martindale: The Complete Drug Reference, 37th ed., Pharmaceutical Press, London, England, UK, 2011.

[13] E.J. Cano, X.F. Fuentes, C.C. Campioli, J.C. O’Horo, O.A. Saleh, Y. Odeyemi, H. Yadav, Z. Temesgen, Impact of corticosteroids in coronavirus disease 2019 outcomes, CHEST 159 (3) (2021) 1019–1040.

[14] R. Huang, C. Zhu, J. Wang, L. Xue, C. Li, X. Yan, S. Huang, B. Zhang, L. Zhu, T. Xu, F. Ming, Y. Zhao, J. Cheng, H. Shao, X. Zhao, D. Sang, H. Zhao, X. Guan, X. Chen, Y. Chen, J. Wei, R. Issa, L. Liu, C. Wu. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients, Euro. J. Pharmacol. 889 (2020) 173556.

[15] K. Chatterjee, C. Wu, A. Bhardwaj, M. Siuba, Steroids in COVID-19: an overview, Cleve. Clin. J. Med. 20 (Aug 2020), https://doi.org/10.3949/ccjm.87a.ccc059.

[16] N. Sharma, A.S. Reddy, K. Yun, Chemosphere 282 (2021) 131029.

[17] C. Liu, Z. Zhou, G. Liu, Q. Wang, J. Chen, L. Wang, Y. Zhou, G. Dong, X. Xu, Y. Wang, Y. Guo, M. Liu, L. Wu, G. Du, C. Wei, X. Zeng, X. Wang, J. Wu, H. Zhou.
Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration, Am. J. Med. 125 (3) (2012) 292–301.

K. Allen, Dexamethasone: An all purpose agent?, Austral Anaesth. (2007) 65–70.

A.E. Coutinho, K.E. Chapman, The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights, Mol. Endocrinol. 1 (1) (2011) 1–2.

S. Shalaya, I.M. Khan, Charge transfer complexes: Emerging and promising colorimetric real-time chemosensors for hazardous materials, J. Hazard. Mater. 403 (2021) 123537.

A.S. Al Attar, M.M. Alshehri, D.S. Al-Raiami, Spectrophotometric determination of some amino heterocyclic donors through charge transfer complex formation with chloralonic acid in acetonitrile, J. Mol. Liq. 148 (2–3) (2009) 58–66.

S. Shalaya, V. Zagor, K. Gotoh, H. Ishida, A. Konnai, D. Asoy, Hydrogen bonding in 1,2-diazine–chloralonic acid (2 : 1) studied by a \( ^{13} \)N nuclear quadrupole coupling tensor and multi-temperature X-ray diffraction, Phys. Chem. Chem. Phys. 11 (13) (2009) 22281–2286.

A.S. Gabbala, C. Wagner, S.M. Teleb, E.M. Nour, M.A.F. Elmoslmany, G.N. Kaladerovic, H. Schmidt, D. Steinborn, Preparation, spectroscopic and structural studies on charge-transfer complexes of 2,9-dimethyl-1,10-phenanthroline with some electron acceptors, J. Mol. Struct. 876 (1–3) (2008) 301–307.

R.S. Mulliken, W.B. Person, Molecular Complexes, Wiley, New York, 1969.

R.S. Mulliken, Structures of complexes formed by halogen molecules with aromatic and with oxygenated solvents, J. Am. Chem. Soc. 72 (1950) 600–608.

R. Foster, Organic Charge-Transfer Complexes, Academic Press, London, 1969.

R.S. Mulliken, Molecular compounds and their spectra. III. The interaction of electron donors and acceptors, J. Phys. Chem. 56 (7) (1952) 801–822.

A.M.A. Adam, H.A. Saad, A.A. Atta, M. Alaswatu, M.S. Hegab, T.A. Altalhi, M.S. Refat, A.I. El-Shafey, Charge-transfer complex formation of 1-methyl-3-trifluoromethyl-2-pyrazoline-5-one with some amino heterocyclic donors through charge transfer, J. Mol. Liq. 334 (2021) 115904.

M.S. Refat, H.A. Saad, A.A. Gobouri, M. Alaswatu, A.M.A. Adam, S.M. El-Meghabril, Charge transfer complexation between some transition metal ions with azo Schiff base donor as a smart precursor for synthesis of nano oxides: An adsorption efficiency for treatment of Congo red dye in wastewater, J. Mol. Liq. 311 (2021) 117140. https://doi.org/10.1016/j.molliq.2021.117140.

A.M.A. Adam, M.S. Refat, T.A. Altalhi, F.S. Aldawsari, G.H. Al-Hazmi, Liquid and solid-state study of charge-transfer (CT) interaction between drug triazene and tetracyanotetraene (TCNQ) as an acceptor, J. Mol. Liq. 336 (2021) 116261.

A.M.A. Adam, M.S. Refat, T.A. Altalhi, K.S. Alsuhaibani, Charge-transfer complexation of TCNQ with azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part IV: A comparison between solid and liquid interactions, J. Mol. Liq. 340 (2021) 117224.

A.M.A. Adam, H.A. Saad, M.A. Alaswatu, M.S. Refat, M.S. Hegab, Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part II: A comparative study on liquid vs solid-solid interactions, J. Mol. Liq. 335 (2021) 116250.

A.M.A. Adam, H.A. Saad, A.M. Alsuhaibani, M.S. Refat, M.S. Hegab, Charge-transfer and H-bonding chemistry of the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part I: Complexation with some amino donors, J. Mol. Liq. 325 (2021) 115121.

A.M.A. Adam, H.A. Saad, A.M. Alsuhaibani, M.S. Refat, M.S. Hegab, Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part I: Complexation with iodine in different solvents, J. Mol. Liq. 325 (2021) 115187.

A.M.A. Adam, M.S. Refat, T.A. Altalhi, F.S. Aldawsari, Charge-transfer (CT) dynamics of triamterene with 2,3-dichloro-5. 6-dicyano-p-benzoquinone acceptor: A \( n \)-\( n^* \) model CT complex generated by liquid- and solid-state reactions, J. Mol. Liq. 334 (2021) 116119.

A.M.A. Adam, T.A. Altalhi, H.A. Saad, A.M. Alsuhaibani, M.S. Refat, M.S. Hegab, Correlations between spectroscopic data for charge-transfer complexes of two artificial sweeteners, aspartame and neotame, generated with several \( n \)-\( n^* \) acceptors, J. Mol. Liq. 334 (2021) 115904.

A.M.A. Adam, T.A. Altalhi, H.A. Saad, M.S. Refat, M.S. Hegab, Exploring the charge-transfer chemistry of fluoro-containing pyrazolin-5-one: The complex formation of 1-methyl-3-trifluoromethyl-2-pyrazoline-5-one with five \( n \)-\( n^* \) acceptors, J. Mol. Liq. 331 (2021) 115814.

A.M.A. Adam, M.S. Refat, A comparison of charge-transfer complexes of iodine with some antibiotics formed through two different approaches (liquid-liquid vs solid-solid), J. Mol. Liq. 329 (2021) 115560.

R.M. Alghanmi, M.T. Basha, S.M. Soliman, R.K. Alsaedi, Synthesis, and spectroscopic, nanostructure, surface morphology, and density functional theory studies of new charge-transfer complexes of anilamphidine with \( n \)-\( n^* \) acceptors, J. Mol. Liq. 326 (2021) 115199.

X. Luo, W. Shi, Y. Yang, Y. Li, Fluorescence probes detecting \( O_2 \) based on intramolecular charge transfer and extended intramolecular proton transfer mechanisms, J. Mol. Liq. 322 (2021) 114886.

S. Halder, R. Aggrawal, K.V. Aswal, D. Ray, S.K. Saha, Study of refolding of a denatured protein and microenvironment probed through FRET to a twisted intramolecular charge transfer fluorescent biosensor molecule, J. Mol. Liq. 322 (2021) 114532.
[108] A.M.A. Adam, M.S. Refat, T. Sharshar, Z.K. Heiba, Synthesis and characterization of highly conductive charge-transfer complexes using positron annihilation spectroscopy, Spectrochim. Acta A 95 (2012) 458–477.

[109] M.S. Refat, H.A. Saad, A.M.A. Adam, Intermolecular hydrogen bond complexes by in situ charge transfer complexation of o-tolidine with picric and chloronic acids, Spectrochim. Acta A 79 (2011) 672–679.

[110] M.S. Refat, H.A. Saad, A.M.A. Adam, Proton transfer complexes based on some π-acceptors having acidic protons with 3-amino-6-[2-(2-thienyl)vinyl]-1,2,4-triazin-5(4H)-one donor: Synthesis and spectroscopic characterizations, J. Mol. Struct. 995 (1–3) (2011) 116–124.

[111] H.A. Benesi, J.H. Hildebrand, A spectrophotometric investigation of the interaction of iodine with aromatic hydrocarbons, J. Am. Chem. Soc. 71 (8) (1949) 2703–2707.

[112] A.B.P. Lever, Inorganic Electronic Spectroscopy, second ed., Elsevier, Amsterdam, 1985.

[113] H. Tsubumora, R. Lang, Molecular complexes and their spectra. XIII. complexes of iodine with amides, diethyl sulfide and diethyl disulfide, J. Am. Chem. Soc. 83 (9) (1961) 2085–2092.

[114] A. Alagha, A. Nourallah, S. Hariri, Characterization of dexamethasone loaded collagen-chitosan sponge and in vitro release study, J. Drug Deliv. Sci. Technol. 55 (2020) 101449.

[115] A. Sanjana, M.G. Ahmed, J. Gowda BH, Preparation and evaluation of in-situ gels containing hydrocortisone for the treatment of aphthous ulcer, J. Oral Biol. Craniofac. Res. 11 (2) (2021) 269–276.

[116] S. Soumya, I. Hubert Joe, A combined experimental and quantum chemical study on molecular structure, spectroscopic properties and biological activity of anti-inflammatory Glucocorticosteroid drug, Dexamethasone, J. Mol. Struct. 1245 (2021) 130999.

[117] A.M.A. Adam, H.A. Saad, A.A. Atta, M. Alsawat, M.S. Hegab, M.S. Refat, T.A. Altalhi, E.H. Alosaimi, A.A.O. Younes, Usefulness of charge-transfer interaction between urea and vacant orbital acceptors to generate novel adsorbent material for the adsorption of pesticides from irrigation water, J. Mol. Liq. 349 (2022) 118118.

[118] A.M.A. Adam, M.S. Refat, Analysis of charge-transfer complexes caused by the interaction of the antihypertensive drug valsartan with several acceptors in CH2Cl2 and CHCl3 solvents and correlations between their spectroscopic parameters, J. Mol. Liq. 348 (2022) 118466.

[119] A.M.A. Adam, H.A. Saad, M.S. Refat, M.S. Hegab, Charge-transfer complexes of antipsychotic drug sulpiride with inorganic and organic acceptors generated through two different approaches: spectral characterization, J. Mol. Liq. 353 (2022) 118819.

[120] A.M.A. Adam, H.A. Saad, A.A. Atta, M. Alsawat, M.S. Hegab, T.A. Altalhi, M.S. Refat, An environmentally friendly method for removing Hg(II), Pb(II), Cd(II) and Sn(II) heavy metals from wastewater using novel metal–carbon-based composites, Crystals 11 (2021) 882, https://doi.org/10.3390/cryst11080882.

[121] A.M.A. Adam, H.A. Saad, A.A. Atta, M. Alsawat, M.S. Hegab, M.S. Refat, T.A. Altalhi, E.H. Alosaimi, A.A.O. Younes, Preparation and characterization of new CrFeO3-carbon composite using environmentally friendly methods to remove organic dye pollutants from aqueous solutions, Crystals 11 (2021) 960, https://doi.org/10.3390/cryst11080960.